Fundamental Analysis of ASTRIA THERAPEUTICS INC(NASDAQ:ATXS) stock

Fundamental Rating

Taking everything into account, ATXS scores 3 out of 10 in our fundamental rating. ATXS was compared to 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ATXS as it has an excellent financial health rating, but there are worries on the profitability. ATXS does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ATXS has reported negative net income.

In the past year ATXS has reported a negative cash flow from operations.

ATXS had negative earnings in each of the past 5 years.

ATXS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -27.66%, ATXS is doing good in the industry, outperforming 71.50% of the companies in the same industry.

With a decent Return On Equity value of -29.28%, ATXS is doing good in the industry, outperforming 79.47% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-27.66%
ROE	-29.28%
ROIC	N/A

ROA(3y)-74.38%

ROA(5y)-72.91%

ROE(3y)-77.59%

ROE(5y)-79.61%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATXS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, ATXS has more shares outstanding

The number of shares outstanding for ATXS has been increased compared to 5 years ago.

There is no outstanding debt for ATXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ATXS has an Altman-Z score of 13.72. This indicates that ATXS is financially healthy and has little risk of bankruptcy at the moment.

ATXS's Altman-Z score of 13.72 is amongst the best of the industry. ATXS outperforms 89.20% of its industry peers.

ATXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	13.72

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ATXS has a Current Ratio of 22.38. This indicates that ATXS is financially healthy and has no problem in meeting its short term obligations.

With an excellent Current ratio value of 22.38, ATXS belongs to the best of the industry, outperforming 95.93% of the companies in the same industry.

ATXS has a Quick Ratio of 22.38. This indicates that ATXS is financially healthy and has no problem in meeting its short term obligations.

ATXS's Quick ratio of 22.38 is amongst the best of the industry. ATXS outperforms 95.93% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	22.38
Quick Ratio	22.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ATXS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.36%.

EPS 1Y (TTM)1.36%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%33.33%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.81% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y28.33%

EPS Next 2Y11.38%

EPS Next 3Y7.62%

EPS Next 5Y11.81%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATXS. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATXS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y11.38%

EPS Next 3Y7.62%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ATXS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ASTRIA THERAPEUTICS INC

NASDAQ:ATXS (12/18/2024, 4:30:01 PM)

After market: 9.36 0 (0%)

9.36

-0.19 (-1.99%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap528.18M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-27.66%
ROE	-29.28%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	22.38
Quick Ratio	22.38
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)1.36%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y28.33%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ASTRIA THERAPEUTICS INC (ATXS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens